Clinical Trial: CAPOX and Bevacizumab With or Without Primary Tumor Radiotherapy and Iparomlimab and Tuvonralimab as First-line Treatment for RAS-Mutant/MSS Metastatic Rectal Cancer

U.S., Feb. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07383285) titled 'CAPOX and Bevacizumab With or Without Primary Tumor Radiotherapy and Iparomlimab and Tuvonralimab as First-line Treatment for RAS-Mutant/MSS Metastatic Rectal Cancer' on Jan. 26.

Brief Summary: Research objective: To compare the efficacy and safety of Capox + Bev versus Capox + Bev combined with primary site radiotherapy + (Iparomlimab and Tuvonralimab) as the first-line treatment for RAS Mutation/pMMR metastatic rectal cancer patients.

Study endpoint:

Primary endpoint: 12-month progression-free survival rate (PFSR)

Secondary endpoints:

* The objective response rate (ORR) and disease control rate (DCR) as determined by the invest...